1. Home
  2. CTKB vs OCS Comparison

CTKB vs OCS Comparison

Compare CTKB & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • OCS
  • Stock Information
  • Founded
  • CTKB 1990
  • OCS 2003
  • Country
  • CTKB United States
  • OCS Switzerland
  • Employees
  • CTKB N/A
  • OCS N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • OCS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • OCS Health Care
  • Exchange
  • CTKB Nasdaq
  • OCS Nasdaq
  • Market Cap
  • CTKB 718.8M
  • OCS 689.8M
  • IPO Year
  • CTKB 2021
  • OCS N/A
  • Fundamental
  • Price
  • CTKB $3.65
  • OCS $18.27
  • Analyst Decision
  • CTKB Buy
  • OCS Strong Buy
  • Analyst Count
  • CTKB 2
  • OCS 4
  • Target Price
  • CTKB $7.00
  • OCS $30.25
  • AVG Volume (30 Days)
  • CTKB 908.8K
  • OCS 48.2K
  • Earning Date
  • CTKB 05-07-2025
  • OCS 05-07-2025
  • Dividend Yield
  • CTKB N/A
  • OCS N/A
  • EPS Growth
  • CTKB N/A
  • OCS N/A
  • EPS
  • CTKB N/A
  • OCS N/A
  • Revenue
  • CTKB $200,453,000.00
  • OCS $757,024.00
  • Revenue This Year
  • CTKB $4.87
  • OCS $57.00
  • Revenue Next Year
  • CTKB $8.74
  • OCS $1,820.89
  • P/E Ratio
  • CTKB N/A
  • OCS N/A
  • Revenue Growth
  • CTKB 3.85
  • OCS N/A
  • 52 Week Low
  • CTKB $3.27
  • OCS $10.79
  • 52 Week High
  • CTKB $7.63
  • OCS $23.08
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 38.95
  • OCS 52.53
  • Support Level
  • CTKB $3.27
  • OCS $14.00
  • Resistance Level
  • CTKB $3.80
  • OCS $16.39
  • Average True Range (ATR)
  • CTKB 0.25
  • OCS 0.94
  • MACD
  • CTKB 0.03
  • OCS 0.22
  • Stochastic Oscillator
  • CTKB 45.78
  • OCS 71.40

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: